If you have PCOS and you're reading about GLP-1 medications, you probably found this page because your doctor mentioned weight loss could help your symptoms — or because you've heard that Ozempic or Mounjaro might improve more than just the number on the scale.
You're right to be curious. The relationship between GLP-1 medications and PCOS is one of the most interesting emerging stories in reproductive endocrinology. And the data is increasingly encouraging.
Why PCOS and GLP-1s are connected
PCOS affects approximately 8-13% of women of reproductive age. It's characterised by hormonal imbalances — specifically elevated androgens (male hormones like testosterone), insulin resistance, and disrupted ovulation. Many women with PCOS also struggle with weight, and the relationship goes both directions: PCOS makes weight gain easier and weight loss harder, while excess weight worsens PCOS symptoms.
Insulin resistance is the thread that ties it all together. Roughly 70-80% of women with PCOS have some degree of insulin resistance, regardless of their weight. High insulin levels stimulate the ovaries to produce more androgens, which drive the symptoms most women find distressing — irregular periods, acne, hair loss, and excess hair growth.
GLP-1 medications improve insulin sensitivity. They reduce circulating insulin levels. They promote weight loss. And through these mechanisms, they address the metabolic root of PCOS rather than just masking individual symptoms.
What the research shows
A meta-analysis examining GLP-1 receptor agonists in women with PCOS found significant improvements across multiple endpoints: reduced body weight, improved insulin sensitivity, decreased testosterone levels, and improved menstrual regularity (Xing et al., 2023). These benefits were observed even in studies with relatively short treatment durations.
The weight loss component matters more than the number itself. Clinical evidence consistently shows that even a 5-10% reduction in body weight can restore ovulatory cycles in many women with PCOS. GLP-1 medications routinely produce weight loss well above this threshold — semaglutide 2.4mg produces ~15%, tirzepatide 15mg produces ~20-22%.
Research specifically examining liraglutide (an earlier GLP-1 medication) in PCOS found improvements in body composition, menstrual regularity, and hormonal profiles beyond what would be expected from weight loss alone — suggesting GLP-1 receptor activation may have direct beneficial effects on reproductive endocrine function (Elkind-Hirsch et al., 2022).
The fertility question
This is where the conversation gets both exciting and cautious.
Many women with PCOS struggle with infertility, primarily because they don't ovulate regularly. When GLP-1 medications improve insulin sensitivity and reduce body weight, ovulation often resumes. There are now widespread anecdotal reports — and growing clinical acknowledgment — of unexpected pregnancies in women starting GLP-1 therapy.
This is sometimes called the "Ozempic baby" phenomenon, and it's real enough that the reproductive endocrinology community has taken notice.
Here's the crucial caveat: GLP-1 medications are not approved for use during pregnancy and should be discontinued before conception. The recommendation is to stop semaglutide at least two months before planned conception, and tirzepatide at least one month before. These medications have not been studied in pregnant women, and the effects on fetal development are unknown.
If you have PCOS and are trying to conceive, GLP-1 medications can be a valuable tool to improve your metabolic health and restore ovulation before conception — but they need to be stopped before you actually become pregnant. Discuss the timing carefully with your doctor.
If you're NOT trying to conceive and you have PCOS, the improvement in ovulatory function means your existing birth control suddenly becomes more important. GLP-1 medications can also reduce the effectiveness of oral contraceptives due to slowed gastric emptying affecting absorption — another critical conversation with your doctor.
Beyond weight: other PCOS benefits
The improvements women with PCOS report on GLP-1 medications extend beyond the scale:
Menstrual regularity: As insulin resistance improves and weight decreases, many women report their periods becoming more regular — sometimes for the first time in years. This is directly related to restored ovulatory function.
Androgen reduction: Lower insulin levels mean less ovarian androgen production. Women often notice improvements in hormonal acne, thinning of excess facial or body hair (though this takes months), and reduced scalp hair loss.
Mood and energy: PCOS is associated with elevated rates of anxiety and depression, partly driven by hormonal imbalances and partly by the metabolic effects of insulin resistance. Large-scale studies of GLP-1 medications have shown associations with reduced depression and anxiety symptoms (McIntyre et al., 2025), which may be particularly relevant for women with PCOS-related mood disturbances.
Metabolic markers: Improvements in blood sugar, cholesterol, and blood pressure are well-documented with GLP-1 therapy. For women with PCOS — who have elevated long-term cardiovascular risk — these metabolic improvements are clinically significant beyond their impact on PCOS symptoms.
What about metformin?
Metformin has been the first-line medication for PCOS with insulin resistance for decades. It works, but modestly — typical weight loss is 2-3% and metabolic improvements are often partial.
GLP-1 medications are dramatically more effective for weight loss and appear to improve insulin sensitivity at least as effectively as metformin in most comparisons. Some doctors now prescribe GLP-1 medications instead of metformin for PCOS; others use them in combination.
If you're currently on metformin and your PCOS symptoms are well-controlled, there's no urgent reason to switch. If metformin isn't providing adequate benefit, a GLP-1 medication may offer significantly better results. This is a conversation worth having with your endocrinologist or gynaecologist.
Practical considerations for women with PCOS
Start with your hormonal medications in mind. If you're on oral contraceptives, discuss timing and absorption with your doctor. If you're on spironolactone or other anti-androgen medications, your doctor may adjust doses as your hormonal profile changes with weight loss.
Track your cycles. If your periods have been absent or irregular, GLP-1 therapy may bring them back. Track what happens — this information is valuable for your doctor.
Don't ignore the pregnancy risk. If you've been told you're unlikely to conceive due to PCOS and you're not actively using contraception, reconsider this assumption once you start GLP-1 therapy. Restored ovulation means restored fertility, sometimes faster than expected.
Prioritise protein and resistance training. This advice applies to all GLP-1 users, but it's especially important for women with PCOS. Insulin resistance improves more with muscle preservation, and adequate protein intake supports the hormonal shifts you're working toward.
Be patient with the hormonal changes. Weight loss happens in weeks to months. Hormonal rebalancing takes longer. Improvements in acne, hair growth patterns, and menstrual regularity may take 3-6 months to become apparent. Give the process time.
The bottom line
PCOS is a metabolic condition that happens to express itself through reproductive symptoms. GLP-1 medications address the metabolic root — insulin resistance, excess weight, hormonal dysregulation — rather than masking individual symptoms. For many women with PCOS, they represent the most effective pharmacological intervention available for the underlying condition.
Talk to your doctor — ideally an endocrinologist or reproductive endocrinologist who understands both PCOS and GLP-1 therapy. The research is encouraging and the clinical experience is growing rapidly.
Key Studies & References
-
Xing et al. (2023) — Meta-analysis of GLP-1 receptor agonists in women with PCOS, showing significant improvements in body weight, insulin sensitivity, testosterone levels, and menstrual regularity. Read the full study
-
Elkind-Hirsch et al. (2022) — Study of liraglutide in PCOS demonstrating improvements in body composition, menstrual function, and hormonal profiles beyond weight loss effects alone. Read the full study
-
McIntyre et al. (2025) — Large-scale analysis showing GLP-1 receptor agonists are associated with reduced risk of depression and anxiety, relevant to the mood disturbances common in PCOS. Read the full study
-
Wilding et al. (2021) — The STEP 1 trial establishing semaglutide's weight-loss efficacy (~15%), providing context for the magnitude of weight loss that can improve PCOS outcomes. Read the full study